-
1.发明申请公开(公告)号：US20090117100A1
公开(公告)日：2009-05-07
申请号：US12288181
申请日：2008-10-16
IPC分类号： A61K39/395 , C07K16/00 , A61P35/00 , C12P21/00 , G01N33/574
CPC分类号： C07K16/28 , A61K38/05 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6851 , A61K47/6869 , A61K47/6889 , A61K2039/505 , C07K16/30 , C07K16/3069 , C07K2317/14 , C07K2317/24 , C07K2317/40 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/73 , C07K2317/77 , G01N33/574 , G01N33/57492
摘要： Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的反应性半胱氨酸氨基酸替代亲本抗TENB2抗体的一个或多个氨基酸来工程化半胱氨酸改造的抗TENB2抗体。 提供了设计，制备，筛选和选择半胱氨酸改造的抗TENB2抗体的方法。 通过接头（L）将半胱氨酸改造的抗TENB2抗体（Ab）与一个或多个药物部分（D）缀合以形成具有式I的半胱氨酸改造的抗TENB2抗体 - 药物共轭物：<β在线配方描述= “直线公式”end =“lead”？> Ab-（LD）p I <？in-line-formula description =“In-line Formulas”end =“tail”？>其中p为1到4.诊断 并公开了半胱氨酸改造的抗体药物化合物和组合物的治疗用途。
-
2.发明授权公开(公告)号：US08937161B2
公开(公告)日：2015-01-20
申请号：US12288181
申请日：2008-10-16
CPC分类号： C07K16/28 , A61K38/05 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6851 , A61K47/6869 , A61K47/6889 , A61K2039/505 , C07K16/30 , C07K16/3069 , C07K2317/14 , C07K2317/24 , C07K2317/40 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/73 , C07K2317/77 , G01N33/574 , G01N33/57492
摘要： Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的反应性半胱氨酸氨基酸替代亲本抗TENB2抗体的一个或多个氨基酸来工程化半胱氨酸改造的抗TENB2抗体。 提供了设计，制备，筛选和选择半胱氨酸改造的抗TENB2抗体的方法。 半胱氨酸改造的抗TENB2抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合以形成具有式I：Ab-（LD）p I的半胱氨酸改造的抗TENB2抗体 - 药物共轭物，其中p 公开了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。
-
公开(公告)号：US20100278842A1
公开(公告)日：2010-11-04
申请号：US12796496
申请日：2010-06-08
申请人： Weiguang Mao , Paul Polakis
发明人： Weiguang Mao , Paul Polakis
IPC分类号： A61K39/395 , C07H21/04 , C12N15/63 , C12N5/10 , C12P21/00 , A61K31/7088 , A61P35/00
CPC分类号： C07K7/08 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K2039/505 , C07K7/06 , C07K16/2866 , C07K2317/77 , C07K2317/92
摘要： The invention provides anti-EphB2 antibodies, immunoconjugates, and compositions comprising and methods of using these antibodies and immunoconjugates.
摘要翻译： 本发明提供抗EphB2抗体，免疫缀合物和包含使用这些抗体和免疫缀合物的组合物。
-
公开(公告)号：US07767205B2
公开(公告)日：2010-08-03
申请号：US11831787
申请日：2007-07-31
申请人： Weiguang Mao , Paul Polakis
发明人： Weiguang Mao , Paul Polakis
IPC分类号： A61K39/395 , C07K16/28 , C07H21/00 , C12N1/21 , C12N15/00 , C12N5/00 , C12P21/04 , G01N33/574
CPC分类号： C07K7/08 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K2039/505 , C07K7/06 , C07K16/2866 , C07K2317/77 , C07K2317/92
摘要： The invention provides anti-EphB2 antibodies, immunoconjugates, and compositions comprising and methods of using these antibodies and immunoconjugates.
摘要翻译： 本发明提供抗EphB2抗体，免疫缀合物和包含使用这些抗体和免疫缀合物的组合物。
-
公开(公告)号：US20080254024A1
公开(公告)日：2008-10-16
申请号：US11831787
申请日：2007-07-31
申请人： Weiguang Mao , Paul Polakis
发明人： Weiguang Mao , Paul Polakis
IPC分类号： A61K39/395 , C07K16/28 , C07H21/00 , C12N15/00 , G01N33/574 , C12N5/00 , C12N1/21 , C12P21/04
CPC分类号： C07K7/08 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K2039/505 , C07K7/06 , C07K16/2866 , C07K2317/77 , C07K2317/92
摘要： The invention provides anti-EphB2 antibodies, immunoconjugates, and compositions comprising and methods of using these antibodies and immunoconjugates.
摘要翻译： 本发明提供抗EphB2抗体，免疫缀合物和包含使用这些抗体和免疫缀合物的组合物。
-
公开(公告)号：US08535675B2
公开(公告)日：2013-09-17
申请号：US12956282
申请日：2010-11-30
申请人： Mark Dennis , Bonnee Rubinfeld , Paul Polakis
发明人： Mark Dennis , Bonnee Rubinfeld , Paul Polakis
IPC分类号： A61K39/00
CPC分类号： C07K16/30 , A61K31/537 , A61K45/06 , A61K47/6803 , A61K47/6809 , A61K47/6813 , A61K47/6817 , A61K47/6849 , A61K47/6851 , A61K47/6857 , A61K47/6869 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K16/3023 , C07K16/3069 , C07K2317/14 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/57423 , G01N33/57449 , G01N33/57492
摘要： The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
-
公开(公告)号：US20120148610A1
公开(公告)日：2012-06-14
申请号：US13397656
申请日：2012-02-15
申请人： Svetlana O. Doronina , Peter D. Senter , Brian E. Toki , Allen J. Ebens , Toni Beth Kline , Paul Polakis , Mark X. Sliwkowski , Susan D. Spencer
发明人： Svetlana O. Doronina , Peter D. Senter , Brian E. Toki , Allen J. Ebens , Toni Beth Kline , Paul Polakis , Mark X. Sliwkowski , Susan D. Spencer
IPC分类号： A61K39/395 , A61P35/00 , C07K16/00
CPC分类号： C07K16/32 , A61K38/00 , A61K47/6803 , A61K47/6811 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K2039/505 , C07K7/02 , C07K2317/24 , Y02A50/414 , Y02A50/423 , Y02A50/469 , Y10T428/13
摘要： Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
-
公开(公告)号：US20120148608A1
公开(公告)日：2012-06-14
申请号：US13397644
申请日：2012-02-15
申请人： Svetlana O. Doronina , Peter D. Senter , Brian E. Toki , Allen J. Ebens , Toni Beth Kline , Paul Polakis , Mark X. Sliwkowski , Susan D. Spencer
发明人： Svetlana O. Doronina , Peter D. Senter , Brian E. Toki , Allen J. Ebens , Toni Beth Kline , Paul Polakis , Mark X. Sliwkowski , Susan D. Spencer
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/32 , A61K38/00 , A61K47/6803 , A61K47/6811 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K2039/505 , C07K7/02 , C07K2317/24 , Y02A50/414 , Y02A50/423 , Y02A50/469 , Y10T428/13
摘要： Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
-
9.发明申请WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS 审中-公开WNT拮抗剂及其在诊断和治疗WNT介导性疾病中的应用公开(公告)号：US20120141481A1
公开(公告)日：2012-06-07
申请号：US13367760
申请日：2012-02-07
IPC分类号： A61K39/395 , A61M37/00 , A61P35/00 , C07K16/18 , C07K14/705
CPC分类号： C07K14/4702 , A61K38/00 , C07K14/71 , G01N2333/71 , Y02A50/473
摘要： The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.
摘要翻译： 本发明提供了包含衍生自卷曲蛋白的Frz结构域组分，分泌的卷曲相关蛋白或Ror蛋白和Fc免疫球蛋白组分的嵌合Wnt拮抗剂，以及它们在细胞Wnt信号传导和Wnt介导的治疗和诊断检测中的用途 疾病，包括癌症。
-
公开(公告)号：US20120003248A1
公开(公告)日：2012-01-05
申请号：US13098393
申请日：2011-04-29
申请人： Svetlana O. Doronina , Peter D. Senter , Brian E. Toki , Allen J. Ebens , Toni Beth Kline , Paul Polakis , Mark X. Sliwkowski , Susan D. Spencer
发明人： Svetlana O. Doronina , Peter D. Senter , Brian E. Toki , Allen J. Ebens , Toni Beth Kline , Paul Polakis , Mark X. Sliwkowski , Susan D. Spencer
IPC分类号： A61K39/395 , A61P35/00 , C07K19/00
CPC分类号： C07K16/32 , A61K38/00 , A61K47/6811 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K2039/505 , C07K7/02 , C07K2317/24 , Y02A50/414 , Y02A50/423 , Y02A50/469 , Y02A50/491 , Y02A50/492 , Y10T428/13
摘要： Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
-
-
-
-
-
-
-
-
-
搜索结果
122 条记录 (耗时 0.065 秒)
